News

The first treatment candidate from Verve Therapeutics to begin clinical trials recently produced positive results. Shares of the biotech collapsed despite results that show VERVE-101 can control ...
Verve Therapeutics, Inc. (NASDAQ:VERV) is a clinical-stage company focused on revolutionizing the treatment of cardiovascular disease through innovative gene-editing approaches.
NEW YORK, Sept. 12, 2024 /PRNewswire/ — The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of VERV ...
Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. Eli Lilly (NYSE: LLY) and Verve Therapeutics announced a "definitive agreement for Lilly ...
Two patients in one of Verve Therapeutics' clinical trials experienced heart attacks. One of those heart attacks is possibly connected to its gene editing therapy. This risky stock just got even ...
What's next for Verve Therapeutics? Verve is scheduled to share more information about VERVE-102 at a medical conference this quarter, including trial data from the treatment at a higher dosage level.
Verve Therapeutics is revolutionizing cardiovascular disease treatment with gene editing medicines and innovative delivery technology. Click here to read more.
Verve Therapeutics' research is in the early stages, making it a speculative investment. Read why VERV stock is worth adding to a watchlist.
Why Verve Therapeutics stock tanked There were no issues on the safety front that clearly indicate trouble ahead for VERVE-101 but the initial portion of the study was less than flawless.